People & Culture
Transparency
Company Information

Conversations, news and perspectives from Bayer’s CEO

Inside Bayer’s Transformation: Bill Anderson on the Road

Bill Anderson often has the opportunity to meet with teams, partners and stakeholders around the world. This page brings together moments that showcase how Team Bayer advances its transformation and works towards our mission “Health for all, Hunger for none.”

Bill Anderson at a Glance

Role:	Chief Executive Officer, Bayer AG
Since:	June 1, 2023
Background:	Chemical engineer with leadership experience across biotechnology and pharmaceuticals, including senior roles at Biogen, Genentech and Roche.
Leadership focus:	Innovation, customer focus, simpler structures, faster execution and long-term value creation.

"Team Bayer has made great progress in reorienting the company. But we’re not done yet."
Bill Anderson
CEO of Bayer

Latest visits of Bill Anderson

From production sites and innovation hubs to public events and international visits, here is a glimpse of how he connects with colleagues, partners and communities across Bayer’s businesses and regions.

Latest Visits

When you create a farm, you become a customer. Not many people would expect a one‑hectare field behind our offices and labs in Monheim. But that’s exactly where our teams show what their work does. You see it right away: · Untreated and treated plants side by side — sometimes it means losing the whole crop. · Better seeds for higher yields — to produce more food from the same field. · Precision technology that sprays only what’s needed — down to a few centimeters. There’s a lot of talk about agriculture. Here, you can actually see it. Thanks to our #TeamBayer colleagues who took me into the field.

Placeholder

Interviews, Keynotes and Public Conversations of Bill Anderson

From interviews with major media outlets to keynote appearances at international events, Bill Anderson speaks about some of the opportunities and challenges shaping Bayer’s environment: innovation, competitiveness, regulation and the conditions needed for long-term investment in health and agriculture.

Wall Street Journal Food Forum

At the Wall Street Journal Food Forum in Chicago, Bill Anderson spoke with WSJ News Editor Annie Gasparro about the future of agriculture and Bayer’s role in it. The conversation covered innovation in areas such as gene editing and crop systems, as well as the legal and regulatory context shaping long-term progress.

Click here o watch the full video

Semafor World Economy Summit

At the Semafor World Economy Summit in Washington, D.C., Bill Anderson spoke about resilience, innovation and the role of AI in pharma and agriculture.

Click here o watch the full video

Opening Keynote at Bitkom Transform:

Bill Anderson,default.jpg

At Germany's leading B2B digital transformation event, Anderson urged tech leaders to prioritize creation over regulation, embrace flatter organizational structures, and adopt a mission-first mindset — placing customer value at the center as companies navigate AI's profound opportunities and challenges.

Click here to watch the full video

Sequoia Capital

Bill Anderson,default.jpg

In this conversation with Sequoia Capital, Bill Anderson shares how Bayer is working to become faster, flatter and less bureaucratic. He speaks about rethinking management, replacing annual planning with 90-day cycles, and creating an organization where ownership, peer feedback and customer value matter more than hierarchy.

Click here to watch the full video

Other relevant topics

Recurring Series with Bill Anderson

Follow regular series featuring Bill Anderson for insights into Bayer’s business performance, scientific innovation and long-term priorities.

Today we’re reporting Bayer’s Half Year 2026 financial results. Our CEO Bill Anderson provides an update on Bayer’s group sales for the last quarter – and an outlook on the rest of 2026 – in 90 seconds.

Bayer’s Q1 2026 results update gives a short view of group sales, quarterly performance, and the outlook for the rest of 2026. CEO Bill Anderson presents the investor update in 90 seconds. The video is intended for viewers tracking Bayer’s financial performance and leadership’s view of the year ahead.

Bayer’s FY 2025 results update looks back at the last full year and ahead to 2026. CEO Bill Anderson summarizes group sales, annual performance, and the company’s outlook in 90 seconds. The video gives investors and other stakeholders a quick overview of the full-year financial picture.

After nine months of 2025, Bayer CEO Bill Anderson shares the company’s Q3 financial results and outlook for the rest of the year. The 90 Days in 90 Seconds format keeps the update brief and investor-focused. The video covers group sales and quarterly performance for viewers following Bayer’s financial communications.

What is CoverCress, and why is it being discussed as a potential feedstock for renewable fuels—including sustainable biofuels? This episode of Science Is Boss explores how gene editing can help turn pennycress from a winter weed into an oilseed crop. Bayer CEO Bill Anderson sits down with Jim Hedges of CoverCress Inc. to explain how trait improvements—such as increasing oil content and reducing challenges can support harvestability and on-farm value.

What matters most in pregnancy nutrition—and why does diet quality matter? In this episode, Bayer CEO Bill Anderson speaks with medical expert Dr. Vipin Babu about micronutrient gaps in women of reproductive age and what the scientific evidence says about Multiple Micronutrient Supplementation (MMS) and prenatal vitamins.

Why do so many disease-driving proteins remain out of reach for today’s medicines? In this Science is Boss conversation, Bill Anderson speaks with Aleksandra Rizo, CEO of Vividion Therapeutics, about small molecules and proteins once considered difficult to drug.

In Zambia’s Eastern Province, Bill Anderson visits maize farmers using improved seed technology. The Science is Boss episode looks at drought-resistant maize varieties and how modern seeds can support smallholder productivity.

Menopause and hot flashes are the subject of this Science is Boss episode. Bayer CEO Bill Anderson speaks with Nicole Hayes and Yesmean Wahdan about the need for hormone-free treatment options.

In this episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Michael Schmidt, a former pharmacist, about how his team transformed Iberogast, a trusted liquid digestive health product for sixty years, into a new convenient soft gel format for U.S. consumers.

In the third episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Jamie Chow, a former radiologist, about how AI is transforming patient care in radiology. Jamie led the clinical team at Blackford, a Bayer-owned provider of AI solutions to healthcare systems. Jamie shares how AI is not a replacement for radiologists, but rather a supplement to their fast-paced, high-stakes work, where patients’ health and safety are on the line. What is current research showing about the performance of AI in mammography? How can AI act as a safety net to catch findings and a tool for triaging acute cases?

In the second episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Brianna White in Bayer's Crop Science division about how her team is making corn shorter and more resistant to extreme weather. What was the inspiration for short corn? How are the tools of biotechnology helping farmers who grow one of the world's most important crops? Check out Bill and Brianna's conversation!

Introducing the new exclusive series, "Science Is Boss," in which our CEO Bill Anderson talks to esteemed scientists at Bayer about their innovative projects. In this episode, Bill and Ruth Shah, a trained cell and molecular biologist, delve into the potential of cell and gene therapies to fundamentally change the way we treat diseases like Parkinson's.

Discover More

Mission & Strategy

Dynamic Shared Ownership

Investor News